ES2193581T3 - Agentes de resonancia magnetica nuclear para la liberacion de agentes terapeuticos. - Google Patents

Agentes de resonancia magnetica nuclear para la liberacion de agentes terapeuticos.

Info

Publication number
ES2193581T3
ES2193581T3 ES98955137T ES98955137T ES2193581T3 ES 2193581 T3 ES2193581 T3 ES 2193581T3 ES 98955137 T ES98955137 T ES 98955137T ES 98955137 T ES98955137 T ES 98955137T ES 2193581 T3 ES2193581 T3 ES 2193581T3
Authority
ES
Spain
Prior art keywords
agents
release
magnetic resonance
chelator
nuclear magnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98955137T
Other languages
English (en)
Inventor
Thomas J Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Application granted granted Critical
Publication of ES2193581T3 publication Critical patent/ES2193581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)

Abstract

Agente de IRM que comprende un quelante y un ión metálico paramagnético que está coordinadamente saturado por dicho quelante y una unidad terapéutica bloqueadora, en donde dicha unidad terapéutica bloqueadora está unida de manera covalente a dicho quelante, de manera que se impide el intercambio rápido de agua en, por lo menos, un punto de coordinación, en donde dicha unidad terapéutica bloqueadora comprende por lo menos un agente terapéuticamente activo, en donde se incrementa el intercambio de agua en por lo menos un punto de coordinación en la liberación de dicho agente terapéuticamente activo a su objetivo fisiológico, resultando en un efecto terapéutico y en la activación del agente de IRM.
ES98955137T 1997-10-27 1998-10-27 Agentes de resonancia magnetica nuclear para la liberacion de agentes terapeuticos. Expired - Lifetime ES2193581T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6332897P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
ES2193581T3 true ES2193581T3 (es) 2003-11-01

Family

ID=22048460

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98955137T Expired - Lifetime ES2193581T3 (es) 1997-10-27 1998-10-27 Agentes de resonancia magnetica nuclear para la liberacion de agentes terapeuticos.

Country Status (8)

Country Link
EP (1) EP1027077B1 (es)
JP (2) JP2001521011A (es)
AU (1) AU750686B2 (es)
CA (1) CA2307332C (es)
DE (1) DE69811931T2 (es)
ES (1) ES2193581T3 (es)
NO (1) NO20002115L (es)
WO (1) WO1999021592A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6770261B2 (en) 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
WO1999025389A2 (en) * 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US6534040B2 (en) * 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
EP1251876A2 (en) * 2000-01-22 2002-10-30 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
AU2001259575A1 (en) * 2000-05-04 2001-11-12 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6656450B2 (en) 2000-07-17 2003-12-02 California Institute Of Technology, Inc. Macrocyclic magnetic resonance imaging contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2003251436A1 (en) * 2002-07-22 2004-02-09 Bracco Imaging S.P.A. Procedures of cellular labelling with paramagnetic complexes for mri applications
EP2708244A1 (en) 2012-09-14 2014-03-19 Stichting Katholieke Universiteit Contrast agent and its use for imaging.
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
WO2019009607A1 (ko) * 2017-07-06 2019-01-10 사회복지법인 삼성생명공익재단 킬레이트 복합체, 이의 제조방법 및 이를 포함하는 진단 및 암 치료용 조성물
CN113164628A (zh) 2018-11-23 2021-07-23 拜耳股份有限公司 造影介质制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269839B (it) * 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
TW319763B (es) * 1995-02-01 1997-11-11 Epix Medical Inc
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
WO1997021431A1 (en) * 1995-12-12 1997-06-19 California Institute Of Technology Cobalt schiff base compounds
AU726914B2 (en) * 1996-04-01 2000-11-23 Epix Pharmaceuticals, Inc. Bioactivated diagnostic imaging contrast agents

Also Published As

Publication number Publication date
DE69811931D1 (de) 2003-04-10
DE69811931T2 (de) 2003-12-18
WO1999021592A1 (en) 1999-05-06
EP1027077A1 (en) 2000-08-16
EP1027077B1 (en) 2003-03-05
CA2307332C (en) 2008-09-16
NO20002115D0 (no) 2000-04-26
NO20002115L (no) 2000-06-23
CA2307332A1 (en) 1999-05-06
AU1201799A (en) 1999-05-17
JP2001521011A (ja) 2001-11-06
AU750686B2 (en) 2002-07-25
JP2008143907A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
ES2193581T3 (es) Agentes de resonancia magnetica nuclear para la liberacion de agentes terapeuticos.
ES2124320T3 (es) Desinfectante de yodo y resina y un procedimiento para su preparacion.
ES2176710T3 (es) Carga de farmaco debilmente basico en liposomas por medio de ionoforos.
BR0315700A (pt) Dispositivo médico implantável que incorpora rapamicina deuterada para a aplicação controlada da mesma
MX9605419A (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2194050T3 (es) Uso de bisfosfonatos para inhibir la resorcion osea tras la implantacion de una protesis osea.
EP0802782A4 (en) PROPHYLACTIC AND THERAPEUTIC TREATMENT OF MAIN SENSITIZATION AND IRRITATION
AR019735A1 (es) Articulo absorbente adaptado para recibir heces
IL186822A0 (en) Electromagnetic treatment device
CA2322461A1 (en) Proton donating actives in absorbent articles
AR029716A1 (es) Productos dermatologicos en forma de hoja
CA2341063A1 (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
MX9504415A (es) Eteres antivirales de isoesteres de sustrato de proteasa de aspartato.
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
NO20020299D0 (no) Behandling og sammensetning for oppnåelse av antialdring av hud med Corneum Protease aktivering
GEP20063755B (en) Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
PT739212E (pt) Utilizacao de interleucina-12 para a prevencao de doenca causada pela reaccao do enxerto contra o hospedeiro
ES2179103T3 (es) Composicion detergente.
BR0112659A (pt) Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo
ES2153035T3 (es) Toallita impregnada con agente farmaceutico.
PT1124566E (pt) Laxativo osmotico nao fermentado para o tratamentoe a prevencao dos cancros colorectais
UY27550A1 (es) Composición para catéter y usos de la misma
GT199600075A (es) Articulo absorbente que tiene puños adaptables.
JP2004537546A5 (es)
Corazziari Need of the ideal drug for the treatment of chronic constipation